Using a prostate cancer in vitro model, the in vitro therapeutic efficacy of 225Ac-PSMA was found to be 4.2 times that of 177Lu-PSMA, and such a difference was solely attributed to the higher relative biological effectiveness (RBE) of 225Ac compared to 177Lu [29]. This evidence concerns the gene FOLH1 and prostate carcinoma.